rivaroxaban,dabigatran,apixaban,tinzaparin,edoxaban
pfizer,bayer,boehringer ingelheim,bms,janssen,leo pharma,daiichi sankyo
['edoxaban', 'rivaroxaban', 'tinzaparin', 'dabigatran', 'apixaban', 'aslan ']
dr. tzu-fei wang presenting population-based retrospective data on the use of doac vs. lmwh for dvt prophylaxis post hip/knee arthroplasty in older adults (&gt;66) with chronic kidney disease. doacs = less vte with more hemorrhage. rivaroxaban was the most common doac (95%) #ash22 